Indication
Xiidra
®
(lifi tegrast ophthalmic solution) 5% is indicated for the
treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
Xiidra is contraindicated in patients with known
hypersensitivity to lifi tegrast or to any of the other
ingredients.
In clinical trials, the most common adverse reactions
reported in 5-25% of patients were instillation site irritation,
dysgeusia and reduced visual acuity. Other adverse
reactions reported in 1% to 5% of the patients were blurred
vision, conjunctival hyperemia, eye irritation, headache,
increased lacrimation, eye discharge, eye discomfort, eye
pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the
solution, patients should not touch the tip of the single-use
container to their eye or to any surface.
Contact lenses should be removed prior to the
administration of Xiidra and may be reinserted 15 minutes
following administration.
Safety and effi cacy in pediatric patients below the age of 17
years have not been established.
References:
1. Xiidra [prescribing information]. East Hanover, NJ: Novartis
Pharmaceuticals Corporation; November 2019. 2. TFOS DEWS II
Research Subcommittee. Report of the Research Subcommittee of the
Tear Film & Ocular Surface Society Dry Eye WorkShop II (2017). Ocul
Surf. 2017;15(3):269-649. 3. FDA approves new medication for dry eye
disease. FDA News Release. July 2016. https://www.fda.gov/news-
events/press-announcements/fda-approves-new-medication-dry-eye-
disease. Accessed March 17, 2020. 4. Food and Drug Administration.
Electronic Orange Book. https://www.fda.gov/media/71474/download.
Accessed March 17, 2020.
There's no FDA-approved
therapeutic equivalent.
2,4
Check out patient resources,
insurance coverage, and
more at Xiidra-ECP.com
Xiidra, the fi rst in a class of LFA-1 antagonists
for Dry Eye Disease, is a prescription eye
drop FDA-approved to treat both signs
and symptoms of the disease.
1,3
Xiidra is the only lymphocyte function-associated antigen-1
(LFA-1) antagonist treatment for Dry Eye Disease
1,2
THERE'S NO
SWIITCHING THIS
For additional safety information, see accompanying Brief Summary of Safety Information on the adjacent
page and Full Prescribing Information on Xiidra-ECP.com.
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080 © 2020 Novartis 3/20 XIA-1387617
